OBJECTIVE: To determine the sensitivity and specificity of symptoms, three HIV-1 RNA assays, a p24 antigen EIA and a third-generation enzyme immunoassay (EIA) antibody test for diagnosis of primary HIV infection (PHI). DESIGN: Prospective cohort in a university research program. PARTICIPANTS: Of 258 eligible persons screened for PHI, 40 had primary/early infection (22 preseroconversion, 18 within 6 months of seroconversion) and 218 did not. Seven participants with preseroconversion HIV-1 from a second center were added for evaluating laboratory tests. MAIN OUTCOME MEASURE: PHI, defined as a negative or indeterminate antibody test with subsequent conversion. Symptom analysis also included persons with antibody conversion of less than 6 months' duration. RESULTS: The symptoms most strongly associated with PHI in multivariate analysis were fever [odds ratio (OR) 5.2; 95% confidence interval (CI) 2.3-11.7] and rash (OR 4.8; 95% CI 2.4-9.8). The sensitivity and specificity, respectively, for detecting preseroconversion HIV infection were: p24 antigen, 79% and 99%; third-generation EIA, 79% and 97%; HIV-1 RNA by branched chain DNA 100% and 95%; HIV-1 RNA by polymerase chain reaction 100% and 97%; HIV-1 RNA by transcription-mediated amplification testing, 100% and 98%. False-positive HIV-1 RNA tests were not reproducible and had values < 3000 copies/ml, while only one person with confirmed PHI was in this range. CONCLUSIONS: Rash and fever indicated the highest risk of PHI. HIV-1 RNA tests are very sensitive for PHI but false-positive results occur. False-positive results can be reduced through duplicate testing and considering tests < 5000 copies/ml as indeterminate results requiring additional testing. p24 antigen was more specific than HIV-1 RNA testing but less sensitive.
OBJECTIVE: To determine the sensitivity and specificity of symptoms, three HIV-1 RNA assays, a p24 antigen EIA and a third-generation enzyme immunoassay (EIA) antibody test for diagnosis of primary HIV infection (PHI). DESIGN: Prospective cohort in a university research program. PARTICIPANTS: Of 258 eligible persons screened for PHI, 40 had primary/early infection (22 preseroconversion, 18 within 6 months of seroconversion) and 218 did not. Seven participants with preseroconversion HIV-1 from a second center were added for evaluating laboratory tests. MAIN OUTCOME MEASURE: PHI, defined as a negative or indeterminate antibody test with subsequent conversion. Symptom analysis also included persons with antibody conversion of less than 6 months' duration. RESULTS: The symptoms most strongly associated with PHI in multivariate analysis were fever [odds ratio (OR) 5.2; 95% confidence interval (CI) 2.3-11.7] and rash (OR 4.8; 95% CI 2.4-9.8). The sensitivity and specificity, respectively, for detecting preseroconversion HIV infection were: p24 antigen, 79% and 99%; third-generation EIA, 79% and 97%; HIV-1 RNA by branched chain DNA 100% and 95%; HIV-1 RNA by polymerase chain reaction 100% and 97%; HIV-1 RNA by transcription-mediated amplification testing, 100% and 98%. False-positive HIV-1 RNA tests were not reproducible and had values < 3000 copies/ml, while only one person with confirmed PHI was in this range. CONCLUSIONS:Rash and fever indicated the highest risk of PHI. HIV-1 RNA tests are very sensitive for PHI but false-positive results occur. False-positive results can be reduced through duplicate testing and considering tests < 5000 copies/ml as indeterminate results requiring additional testing. p24 antigen was more specific than HIV-1 RNA testing but less sensitive.
Authors: Bonita E Lee; Sabrina S Plitt; Gayatri C Jayaraman; Linda Chui; Ameeta E Singh; Jutta K Preiksaitis Journal: J Clin Microbiol Date: 2011-12-07 Impact factor: 5.948
Authors: Philip A Chan; Shahzeb Kazi; Amaad Rana; Ilyse Blazar; Colette C Dejong; Kenneth H Mayer; Thomas K Huard; Kim Carleton; Fizza Gillani; Nicole Alexander; Zoanne Parillo; Timothy P Flanigan; Rami Kantor Journal: AIDS Res Hum Retroviruses Date: 2012-07-25 Impact factor: 2.205
Authors: A C Karlsson; J M Chapman; B D Heiken; R Hoh; E G Kallas; J N Martin; F M Hecht; S G Deeks; D F Nixon Journal: J Virol Date: 2007-08-01 Impact factor: 5.103
Authors: Marilia Rita Pinzone; Erin Graf; Lindsay Lynch; Brigit McLaughlin; Frederick M Hecht; Mark Connors; Stephen A Migueles; Wei-Ting Hwang; Giuseppe Nunnari; Una O'Doherty Journal: J Virol Date: 2016-11-14 Impact factor: 5.103
Authors: Markus Moll; Jennifer Snyder-Cappione; Gerald Spotts; Frederick M Hecht; Johan K Sandberg; Douglas F Nixon Journal: Blood Date: 2005-12-20 Impact factor: 22.113
Authors: Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom Journal: Curr HIV/AIDS Rep Date: 2015-06 Impact factor: 5.071
Authors: Merlin L Robb; Leigh A Eller; Hannah Kibuuka; Kathleen Rono; Lucas Maganga; Sorachai Nitayaphan; Eugene Kroon; Fred K Sawe; Samuel Sinei; Somchai Sriplienchan; Linda L Jagodzinski; Jennifer Malia; Mark Manak; Mark S de Souza; Sodsai Tovanabutra; Eric Sanders-Buell; Morgane Rolland; Julie Dorsey-Spitz; Michael A Eller; Mark Milazzo; Qun Li; Andrew Lewandowski; Hao Wu; Edith Swann; Robert J O'Connell; Sheila Peel; Peter Dawson; Jerome H Kim; Nelson L Michael Journal: N Engl J Med Date: 2016-05-18 Impact factor: 91.245